Patients of color who were diagnosed with lung cancer were associated with worse outcomes compared with Caucasian patients, according to findings from the 3rd Annual “State of Lung Cancer” Report by the American Lung Association.
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm…
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment…
Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients…
In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3…
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and…
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the efficacy data behind the use of pacritinib in patients with myelofibrosis in the first article…
